Logo image of BGNE

BEIGENE LTD-ADR (BGNE) Stock Fundamental Analysis

NASDAQ:BGNE - Nasdaq - US07725L1026 - ADR - Currency: USD

184.71  +0.9 (+0.49%)

After market: 184.71 0 (0%)

Fundamental Rating

3

Overall BGNE gets a fundamental rating of 3 out of 10. We evaluated BGNE against 571 industry peers in the Biotechnology industry. BGNE may be in some trouble as it scores bad on both profitability and health. BGNE is valued quite expensive, but it does show an excellent growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

BGNE had negative earnings in the past year.
BGNE had a negative operating cash flow in the past year.
In the past 5 years BGNE always reported negative net income.
BGNE had a negative operating cash flow in each of the past 5 years.
BGNE Yearly Net Income VS EBIT VS OCF VS FCFBGNE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -2B -4B -6B -8B -10B

1.2 Ratios

BGNE's Return On Assets of -15.97% is amongst the best of the industry. BGNE outperforms 81.63% of its industry peers.
Looking at the Return On Equity, with a value of -26.99%, BGNE belongs to the top of the industry, outperforming 80.74% of the companies in the same industry.
Industry RankSector Rank
ROA -15.97%
ROE -26.99%
ROIC N/A
ROA(3y)-21.61%
ROA(5y)-31.52%
ROE(3y)-32.05%
ROE(5y)-48.63%
ROIC(3y)N/A
ROIC(5y)N/A
BGNE Yearly ROA, ROE, ROICBGNE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -20 -40 -60 -80 -100

1.3 Margins

With an excellent Gross Margin value of 83.13%, BGNE belongs to the best of the industry, outperforming 87.63% of the companies in the same industry.
BGNE's Gross Margin has been stable in the last couple of years.
BGNE does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 83.13%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.09%
GM growth 5Y-0.25%
BGNE Yearly Profit, Operating, Gross MarginsBGNE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -2K -4K -6K -8K -10K

More info and screens

3

2. Health

2.1 Basic Checks

BGNE does not have a ROIC to compare to the WACC, probably because it is not profitable.
BGNE has more shares outstanding than it did 1 year ago.
BGNE has more shares outstanding than it did 5 years ago.
The debt/assets ratio for BGNE is higher compared to a year ago.
BGNE Yearly Shares OutstandingBGNE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M
BGNE Yearly Total Debt VS Total AssetsBGNE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 10B 20B 30B 40B 50B

2.2 Solvency

An Altman-Z score of 3.53 indicates that BGNE is not in any danger for bankruptcy at the moment.
BGNE's Altman-Z score of 3.53 is fine compared to the rest of the industry. BGNE outperforms 77.03% of its industry peers.
A Debt/Equity ratio of 0.31 indicates that BGNE is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.31, BGNE is not doing good in the industry: 71.02% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.31
Debt/FCF N/A
Altman-Z 3.53
ROIC/WACCN/A
WACC10.79%
BGNE Yearly LT Debt VS Equity VS FCFBGNE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 10B -10B 20B 30B

2.3 Liquidity

A Current Ratio of 1.94 indicates that BGNE should not have too much problems paying its short term obligations.
BGNE has a worse Current ratio (1.94) than 76.68% of its industry peers.
A Quick Ratio of 1.72 indicates that BGNE should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.72, BGNE is doing worse than 79.15% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.94
Quick Ratio 1.72
BGNE Yearly Current Assets VS Current LiabilitesBGNE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 10B 20B 30B 40B

More info and screens

7

3. Growth

3.1 Past

BGNE shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -457.37%.
The Revenue has grown by 52.08% in the past year. This is a very strong growth!
Measured over the past years, BGNE shows a very strong growth in Revenue. The Revenue has been growing by 67.79% on average per year.
EPS 1Y (TTM)-457.37%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-159.34%
Revenue 1Y (TTM)52.08%
Revenue growth 3Y101.8%
Revenue growth 5Y67.79%
Sales Q2Q%26.79%

3.2 Future

BGNE is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 77.27% yearly.
The Revenue is expected to grow by 25.88% on average over the next years. This is a very strong growth
EPS Next Y35.87%
EPS Next 2Y36.2%
EPS Next 3Y34.59%
EPS Next 5Y77.27%
Revenue Next Year52.03%
Revenue Next 2Y37.72%
Revenue Next 3Y30.68%
Revenue Next 5Y25.88%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
BGNE Yearly Revenue VS EstimatesBGNE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 20B 40B 60B
BGNE Yearly EPS VS EstimatesBGNE Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 500 1K 1.5K 2K

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BGNE. In the last year negative earnings were reported.
Also next year BGNE is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BGNE Price Earnings VS Forward Price EarningsBGNE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50 -100 -150

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BGNE Per share dataBGNE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 -20 -40

4.3 Compensation for Growth

A more expensive valuation may be justified as BGNE's earnings are expected to grow with 34.59% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.2%
EPS Next 3Y34.59%

More info and screens

0

5. Dividend

5.1 Amount

BGNE does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BEIGENE LTD-ADR

NASDAQ:BGNE (12/31/2024, 8:10:09 PM)

After market: 184.71 0 (0%)

184.71

+0.9 (+0.49%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2024-11-12/amc
Earnings (Next)N/A N/A
Inst Owners28.08%
Inst Owner Change-98.45%
Ins OwnersN/A
Ins Owner Change2.67%
Market Cap19.67B
Analysts81.82
Price Target185.96 (0.68%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0.1
Dividend Growth(5Y)N/A
DP-2.03%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-414.4%
Min EPS beat(2)-805.99%
Max EPS beat(2)-22.81%
EPS beat(4)0
Avg EPS beat(4)-490.89%
Min EPS beat(4)-999.2%
Max EPS beat(4)-22.81%
EPS beat(8)1
Avg EPS beat(8)-245.79%
EPS beat(12)2
Avg EPS beat(12)-169.29%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)14.14%
Min Revenue beat(2)0.26%
Max Revenue beat(2)28.03%
Revenue beat(4)4
Avg Revenue beat(4)14.86%
Min Revenue beat(4)0.26%
Max Revenue beat(4)28.03%
Revenue beat(8)8
Avg Revenue beat(8)17.74%
Revenue beat(12)11
Avg Revenue beat(12)13.77%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-16.41%
PT rev (3m)-12.24%
EPS NQ rev (1m)-0.26%
EPS NQ rev (3m)55.77%
EPS NY rev (1m)0.26%
EPS NY rev (3m)11.38%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)30.05%
Revenue NY rev (1m)0.71%
Revenue NY rev (3m)6.64%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 6.09
P/FCF N/A
P/OCF N/A
P/B 5.96
P/tB 6.18
EV/EBITDA N/A
EPS(TTM)-49.45
EYN/A
EPS(NY)-1.18
Fwd EYN/A
FCF(TTM)-10.5
FCFYN/A
OCF(TTM)-5.42
OCFYN/A
SpS30.34
BVpS30.97
TBVpS29.87
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -15.97%
ROE -26.99%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 83.13%
FCFM N/A
ROA(3y)-21.61%
ROA(5y)-31.52%
ROE(3y)-32.05%
ROE(5y)-48.63%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.09%
GM growth 5Y-0.25%
F-Score4
Asset Turnover0.58
Health
Industry RankSector Rank
Debt/Equity 0.31
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales 16.74%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.94
Quick Ratio 1.72
Altman-Z 3.53
F-Score4
WACC10.79%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)25.9%
Cap/Sales(5y)29.08%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-457.37%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-159.34%
EPS Next Y35.87%
EPS Next 2Y36.2%
EPS Next 3Y34.59%
EPS Next 5Y77.27%
Revenue 1Y (TTM)52.08%
Revenue growth 3Y101.8%
Revenue growth 5Y67.79%
Sales Q2Q%26.79%
Revenue Next Year52.03%
Revenue Next 2Y37.72%
Revenue Next 3Y30.68%
Revenue Next 5Y25.88%
EBIT growth 1Y29.36%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year53.98%
EBIT Next 3Y32.29%
EBIT Next 5Y33.22%
FCF growth 1Y33.26%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y55.76%
OCF growth 3YN/A
OCF growth 5YN/A